gdc
Multiple Myeloma

Oral Treatment vs. Others

Jack Aiello offers insights into oral medications as opposed to other treatments and why orals can be more challenging due to potential patient issues.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

Patients do have different issues associated with oral drugs versus infused, or drugs given by shots. For one thing, the latter two are done at a clinician's office, and you have an appointment. You have to make your appointment, and they bring you in, and give you that treatment.

Oral drugs on the other hand, are more dependent on the patient to make sure that they themselves are taking that treatment. There are issues not only to make sure that they are taking them, but how should they be taking them?

Should they be taken with food, without food? What if I miss an oral treatment, is it OK to take it or should I wait till the next treatment cycle? What if they throw up that capsule or treatment, what do I do there? There are issues associated with oral treatments that patients have to understand.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
By Jill Meyer-Lippert, RDH, Amanda Swiecichowski, RN, BSN, CHPN
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
FDA Approvals, News & UpdatesMultiple Myeloma
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country